ASB-13 Activators

The chemical class of ASB-13 activators includes a range of compounds that indirectly influence the activity of ASB-13, primarily through modulation of protein ubiquitination, degradation pathways, and cellular stress responses. This group encompasses various proteasome inhibitors like MG132, Bortezomib, Lactacystin, Velcade, and Epoxomicin. These inhibitors affect the ubiquitin-proteasome system, potentially altering the degradation pathways in which ASB-13 is involved, thereby influencing its activity in protein turnover processes.

Additionally, compounds targeting specific aspects of ubiquitination and protein stability, such as PYR-41, MLN4924, and IU1, contribute to this class by impacting ubiquitin activation, neddylation processes, and deubiquitination mechanisms. Thalidomide's role in modulating E3 ubiquitin ligase activity, Nutlin-3's disruption of MDM2-p53 interaction, and 17-AAG's inhibition of Hsp90 further illustrate the indirect mechanisms through which ASB-13 activity might be modulated. Moreover, compounds like Chloroquine, which inhibits autophagy, underscore the interconnected nature of cellular degradation pathways, including both the ubiquitin-proteasome system and autophagic processes. By influencing these pathways, these compounds indirectly affect the functional dynamics of ASB-13 in protein ubiquitination and degradation.